The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...
2d
French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...
are bispecific antibodies that activate T cells by targeting CD3 and that have been approved for the treatment of triple-class–exposed relapsed or refractory multiple myeloma. A total of 94 ...
A CD38 monoclonal antibody, Sarclisa binds to a specific epitope on the CD38 receptor on myeloma cells, ultimately inducing ...
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...
IASO Bio’s FUCASO ® (equecabtagene autoleucel), a BCMA CAR-T program approved in China for the treatment of patients with ...
If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory ...
Delayed diagnosis causes a significant disadvantage for Hungarian patients adding cost and complexity to the already stretched healthcare system.
China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma: Paris Tuesday, January 14, 2025, 10:00 Hrs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback